Audit-and-feedback to Improve Antimicrobial-prescribing Among Urologists

NACompletedINTERVENTIONAL
Enrollment

525

Participants

Timeline

Start Date

August 1, 2022

Primary Completion Date

July 31, 2023

Study Completion Date

August 31, 2023

Conditions
Urologic DiseasesAntibacterial Drug Adverse Reaction
Interventions
BEHAVIORAL

Audit-and-feedback

We will provide feedback both at baseline and at regular intervals to the 3 intervention sites. At first, we will schedule one-on-one conference calls with urology providers and the antimicrobial stewardship team at each of the 3 intervention sites. These conference calls will include a review of guidelines, a review of the facility's data on excessive post-procedural antimicrobial use for urologic patients, and an anonymous comparison to all other VHA sites. Next, we will prospectively monitor excessive post-procedural antimicrobial use at all 3 sites and the entire VHA for 1 year. Data on hospital-level excessive post-procedural antimicrobial use specific to urologic patients (primary outcome) will be sent electronically to urology providers and the antimicrobial stewardship team at the intervention site every other month via electronic mail.

Trial Locations (3)

10010

VA New York Harbor Healthcare System (Brooklyn), New York

52246

Iowa City VA Medical Center, Iowa City

32608-1135

VA North Florida/South Georgia Veterans Health System, Gainesville

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Iowa City Veterans Affairs Medical Center

FED